Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | 60 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Sep. 12, 2018 |
Dec. 22, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
Dec. 31, 2017 |
|
| Patent and licensing costs | $ 133,985 | $ 161,119 | $ 594,798 | $ 648,867 | |||
| Deferred setup and organization costs, amortization period | 180 months | ||||||
| Unrecognized tax benefits | |||||||
| Tax Reform Law [Member] | |||||||
| Federal corporate tax rate | 21.00% | ||||||
| Theradex Systems, Inc [Member] | |||||||
| Total estimated clinical costs to be charged to operations | $ 2,233,248 | ||||||
| Percentage of clinical trial service | 60.00% | ||||||
| Percentage of clinical center laboratory cost | 40.00% | ||||||
| Clinical costs charged to operations | $ 40,225 | $ 104,840 | |||||
| Percentage of research and development costs | 20.00% | 29.00% | |||||
| Theradex Systems, Inc [Member] | |||||||
| Research and development, description | Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services rendered and payments for pass-through costs of approximately 6%. | ||||||
| Costs under work | $ 954,000 | ||||||